{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:30:53Z","timestamp":1794853853380,"version":"4.9.1"},"reference-count":25,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1D1A1A02086383"],"award-info":[{"award-number":["2018R1D1A1A02086383"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1A2C1009770"],"award-info":[{"award-number":["2022R1A2C1009770"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1I1A1A01069887"],"award-info":[{"award-number":["2022R1I1A1A01069887"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>[177Lu]Ludotadipep, which enables targeted delivery of beta-particle radiation to prostate tumor cells, had been suggested as a promising therapeutic option for mCRPC. From November 2020 to March 2022, a total of 30 patients were enrolled for single dose of [177Lu]Ludotadipep RPT, 6 subjects in each of the 5 different activity groups of 1.9 GBq, 2.8 GBq, 3.7 GBq, 4.6 GBq, and 5.6 GBq. [177Lu]Ludotadipep was administered via venous injection, and patients were hospitalized for three days to monitor for any adverse effects. Serum PSA levels were followed up at weeks 1, 2, 3, 4, 6, 8, and 12, and PSMA PET\/CT with [18F]Florastamin was obtained at baseline and again at weeks 4 and 8. The subjects required positive PSMA PET\/CT prior to [177Lu]Ludotadipep administration. Among the 29 subjects who received [177Lu]Ludotadipep, 36 treatment emergent adverse events (TEAEs) occurred in 17 subjects (58.6%) and 4 adverse drug reactions (ADRs) in 3 subjects (10.3%). Of the total 24 subjects who had full 12-week follow-up data, 16 (66.7%) showed decrease in PSA of any magnitude, and 9 (37.5%) showed a decrease in PSA by 50% or greater. A total of 5 of the 24 patients (20.8%) showed disease progression (PSA increase of 25% or higher from the baseline) at the 12th week following single dose of [177Lu]Ludotadipep. These data thus far suggest that [177Lu]Ludotadipep could be a promising RPT agent with low toxicity in mCRPC patients who have not been responsive to conventional treatments.<\/jats:p>","DOI":"10.3390\/cancers14246225","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T08:41:41Z","timestamp":1671439301000},"page":"6225","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [177Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8496-8825","authenticated-orcid":false,"given":"Dongho","family":"Shin","sequence":"first","affiliation":[{"name":"Department of Urology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunggyun","family":"Ha","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-5915","authenticated-orcid":false,"given":"Joo Hyun","family":"O","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung ah","family":"Rhew","sequence":"additional","affiliation":[{"name":"Department of Urology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Eil","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Urology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeok Jae","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Urology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-3411","authenticated-orcid":false,"given":"Hyong Woo","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Urology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Hyun","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Urology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya Youngju","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chansoo","family":"Park","sequence":"additional","affiliation":[{"name":"Research Institute of Labeling, FutureChem Co., Ltd., Seoul 04793, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9862-3286","authenticated-orcid":false,"given":"Dae Yoon","family":"Chi","sequence":"additional","affiliation":[{"name":"Research Institute of Labeling, FutureChem Co., Ltd., Seoul 04793, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ie Ryung","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6775-1157","authenticated-orcid":false,"given":"Ji Youl","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Urology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: A systematic review","volume":"75","author":"Arfi","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat. Clin. Pract. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1159\/000217264","article-title":"Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer","volume":"76","author":"Sella","year":"2009","journal-title":"Oncology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: A systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int. J. Clin. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.121.262411","article-title":"The European Association of Urology biochemical recurrence risk groups predict findings on PSMA PET in patients with biochemically recurrent prostate cancer after radical prostatectomy","volume":"63","author":"Dong","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101722","DOI":"10.1016\/j.pneurobio.2019.101722","article-title":"N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications","volume":"184","author":"Neale","year":"2020","journal-title":"Prog. Neurobiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2025710119","DOI":"10.1073\/pnas.2025710119","article-title":"Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells","volume":"119","author":"Bakht","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/MOU.0000000000000486","article-title":"Prostate-specific membrane antigen theranostics: Therapy with lutetium-177","volume":"28","author":"Ferdinandus","year":"2018","journal-title":"Curr. Opin. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lisney, A.R., Leitsmann, C., Strau\u00df, A., Meller, B., Bucerius, J.A., and Sahlmann, C.-O. (2022). The Role of PSMA PET\/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer\u2014A Practical Clinical Review. Cancers, 14.","DOI":"10.3390\/cancers14153638"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s13139-022-00764-4","article-title":"Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization","volume":"56","author":"Oh","year":"2022","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1158\/1535-7163.MCT-21-0251","article-title":"Improving Theranostic Gallium-68\/Lutetium-177\u2013Labeled PSMA Inhibitors with an Albumin Binder for Prostate CancerA Novel 177Lu-PSMA Ligand for Prostate Cancer Therapy","volume":"20","author":"Lee","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00259-020-04883-y","article-title":"A microdose clinical trial to evaluate [18F] Florastamin as a positron emission tomography imaging agent in patients with prostate cancer","volume":"48","author":"Lee","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","article-title":"PSMA-RADS version 1.0: A step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies","volume":"73","author":"Rowe","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/cncr.32072","article-title":"Phase 1\/2 study of fractionated dose lutetium-177\u2013labeled anti\u2013prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer","volume":"125","author":"Tagawa","year":"2019","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","article-title":"First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"46","author":"Zang","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","article-title":"Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hofman, M.S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A.M., Goh, J.C., Pattison, D.A., Tan, T.H., Kirkwood, I.D., and Francis, R.J. (2022). TheraP: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Progressing after Docetaxel\u2014Overall Survival after Median Follow-Up of 3 Years (ANZUP 1603), American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2022.40.16_suppl.5000"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13629-020-00300-z","article-title":"Lutetium-177-PSMA therapy for prostate cancer patients-a brief overview of the literature","volume":"10","author":"Braat","year":"2020","journal-title":"Tijdschr. Voor Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: Safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","article-title":"The salivary glands as a dose limiting organ of PSMA-targeted radionuclide therapy: A review of the lessons learnt so far","volume":"98\u201399","author":"Heynickx","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13550-018-0408-2","article-title":"Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands","volume":"8","author":"Lam","year":"2018","journal-title":"EJNMMI Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/24\/6225\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:43:08Z","timestamp":1760146988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/24\/6225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":25,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["cancers14246225"],"URL":"https:\/\/doi.org\/10.3390\/cancers14246225","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]}}}